INVO Bioscience, Inc. (INVO)
NASDAQ: INVO · Real-Time Price · USD
0.690
-0.031 (-4.34%)
Oct 10, 2024, 1:39 PM EDT - Market open
INVO Bioscience Revenue
INVO Bioscience had revenue of $1.84M in the quarter ending June 30, 2024, with 481.38% growth. This brings the company's revenue in the last twelve months to $5.77M, up 390.03% year-over-year. In the year 2023, INVO Bioscience had annual revenue of $3.02M with 267.38% growth.
Revenue (ttm)
$5.77M
Revenue Growth
+390.03%
P/S Ratio
0.35
Revenue / Employee
$192,318
Employees
30
Market Cap
2.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.02M | 2.20M | 267.38% |
| Dec 31, 2022 | 822.20K | -3.34M | -80.24% |
| Dec 31, 2021 | 4.16M | 3.12M | 301.06% |
| Dec 31, 2020 | 1.04M | -442.93K | -29.92% |
| Dec 31, 2019 | 1.48M | 985.84K | 199.41% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Healthcare Triangle | 21.93M |
| Sonoma Pharmaceuticals | 12.70M |
| ReShape Lifesciences | 8.05M |
| InMed Pharmaceuticals | 4.60M |
| Fresh2 Group | 2.34M |
INVO News
- 5 months ago - INVO Reports Record First Quarter 2024 Financial Results - GlobeNewsWire
- 6 months ago - INVO Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 10 months ago - NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal - PRNewsWire
- 11 months ago - NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies - PRNewsWire
- 11 months ago - INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement - PRNewsWire
- 11 months ago - INVO Reports Record Third Quarter 2023 Financial Results - PRNewsWire
- 11 months ago - NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger - PRNewsWire
- 11 months ago - INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase Warrants - PRNewsWire